Enzaplatovir
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02558413)
Timeline
Indications
Mechanism of action
- RSV F-proteinINHIBITOR
RSV F-protein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bta-c585
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02718937 | Phase 2 | Mar 1, 2016 | Aviragen Therapeutics |
| NCT02668367 | Phase 1 | Nov 1, 2015 | Aviragen Therapeutics |
| NCT02558413 | Phase 1 | Aug 1, 2015 | Aviragen Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aviragen Therapeutics | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1